CureVac announced the second- and third-phase trial results for its CVnCoV vaccine on Wednesday, in its final analysis for a 40,000-subject study that drew participants from 10 countries across Europe and Latin America. “In the unprecedented context of 15 strains circulating within the study population at the time of final …
Read More »
Preliminary results from second and third-phase trials on 40,000 subjects in 10 countries of Europe and Latin America show that CureVac’s jab “did not meet pre-specified statistical success criteria,” the company announced on Wednesday. “In the unprecedented context of at least 13 variants circulating within the study population subset assessed …
Read More »
The randomized and placebo-controlled trial called Herald may include more than 35,000 participants in Europe and Latin America, the Tübingen-based company announced. It added that the first participant has been enrolled in the pivotal study of a mRNA vaccine candidate, CvnCoV. “With the start of the pivotal Phase 2b/3 study, …
Read More »